ursolic acid Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Glycyrrhizin, a component of Chinese medicine licorice root. In Japan glycyrrhizin has been used for more than 20 years as treatment for chronic hepatitis and improves liver function with occasional complete recovery from hepatitis. In randomized controlled trials, glycyrrhizin induced a significant reduction of serum aminotransferases and an improvement in liver histology compared to placebo. Intravenous glycyrrhizin can be used safely and be useful for patients with difficult-to-diagnose acute liver disease as an 'initial' treatment tool to improve liver inflammation before starting disease-specific treatments. The mechanism of anti-inflammatory effect of glycyrrhizin most probably does not involve ROS and this major constituent is not responsible for the inhibition effects of liquorice extract on neutrophil functions.   NCATS

Chemistry

  • SMILES: CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]3(C)[C@@H]2C(=O)C=C4[C@@H]5C[C@](C)(CC[C@]5(C)CC[C@@]34C)C(=O)O)O[C@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O[C@@H]7O[C@@H]([C@@H](O)[C@H](O)[C@H]7O)C(=O)O)C(=O)O
  • InChIKey: LPLVUJXQOOQHMX-QWBHMCJMSA-N
  • Mol. Mass: 822.94
  • ALogP: 2.25
  • ChEMBL Molecules:
    glycyrrhizin  
    glycyrrhizinate dipotassium  
    enoxolone  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

18beta-glycyrrhizic acid | (3 beta)-3-hydroxyurs-12-en-28-oic acid | 3-epi-ursolic acid | arthrodont | biosone | e958 | enoxolone | glycyron | glycyrrhetic acid | glycyrrhetin | glycyrrhetinic acid | glycyrrhetinic acid glycoside | glycyrrhizic acid | glycyrrhizin | glycyrrhizinate dipotassium | glycyrrhizinic acid | merotaine | nsc-35347 | nsc-35350 | rhetinic acid | subglycyrrhelinic acid | uralenic acid | ursolic acid | ursolic acid, (3beta)-isomer, 2-(14)c-labeled | ursolic acid, (3beta)-isomer, monopotassium salt

Organizations (11)

Research & Development (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (1)


 

Hepatitis C, Chronic (approved 1948)

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Cardiomyopathies ()

Cholangitis, Sclerosing (Phase 1)

Depressive Disorder (Phase 1/Phase 2)

Dermatitis ()

Erythema (Phase 1)

Hepatitis, Autoimmune (Phase 1)

Hepatitis B, Chronic ()

Hepatitis C, Chronic (Phase 3)

Inflammation ()

Insulin Resistance (Phase 2)

Kidney Failure, Chronic (Phase 2)

Leukemia ()

Metabolic Syndrome (Phase 2)

Muscle Hypotonia (Phase 2)

Muscular Atrophy (Phase 2)

Ovarian Neoplasms ()

Paraplegia (Phase 2)

Pharmacology (Early Phase 1)

Prostatic Neoplasms (Early Phase 1)

Quadriplegia (Phase 2)

Sarcopenia (Phase 2/Phase 3)

Spinal Cord Injuries (Phase 2)

Steroids (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial Organizations: 11

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue